Vaccinex, Inc. (VCNX): Price and Financial Metrics

Vaccinex, Inc. (VCNX): $0.59

0.00 (0.00%)

POWR Rating

Component Grades













Add VCNX to Watchlist
Sign Up

Industry: Biotech



in industry

VCNX Stock Summary

  • VCNX's price/sales ratio is 508.36; that's higher than the P/S ratio of 99.11% of US stocks.
  • With a year-over-year growth in debt of -52.03%, VACCINEX INC's debt growth rate surpasses just 5.09% of about US stocks.
  • As for revenue growth, note that VCNX's revenue has grown -94.44% over the past 12 months; that beats the revenue growth of merely 1.08% of US companies in our set.
  • Stocks that are quantitatively similar to VCNX, based on their financial statements, market capitalization, and price volatility, are DBVT, SONN, CANF, IPSC, and PULM.
  • Visit VCNX's SEC page to see the company's official filings. To visit the company's web site, go to

VCNX Valuation Summary

  • VCNX's price/sales ratio is 510; this is 24185.71% higher than that of the median Healthcare stock.
  • VCNX's price/sales ratio has moved up 200.5 over the prior 54 months.

Below are key valuation metrics over time for VCNX.

Stock Date P/S P/B P/E EV/EBIT
VCNX 2023-01-30 510 4.0 -1.3 -1.0
VCNX 2023-01-27 514 4.1 -1.3 -1.0
VCNX 2023-01-26 504 4.0 -1.3 -1.0
VCNX 2023-01-25 496 3.9 -1.3 -0.9
VCNX 2023-01-24 512 4.1 -1.3 -1.0
VCNX 2023-01-23 498 3.9 -1.3 -0.9

VCNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCNX has a Quality Grade of D, ranking ahead of 11.88% of graded US stocks.
  • VCNX's asset turnover comes in at 0.069 -- ranking 295th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VCNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.069 0.999 12.119
2021-03-31 0.092 0.999 9.215
2020-12-31 0.065 0.997 8.045
2020-09-30 0.080 0.997 7.020
2020-06-30 0.069 0.980 6.213
2020-03-31 0.063 0.944 5.545

VCNX Price Target

For more insight on analysts targets of VCNX, see our VCNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1 (Strong Buy)

VCNX Stock Price Chart Interactive Chart >

Price chart for VCNX

VCNX Price/Volume Stats

Current price $0.59 52-week high $2.28
Prev. close $0.59 52-week low $0.41
Day low $0.57 Volume 96,269
Day high $0.65 Avg. volume 51,250
50-day MA $0.62 Dividend yield N/A
200-day MA $0.86 Market Cap 29.43M

Vaccinex, Inc. (VCNX) Company Bio

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.

VCNX Latest News Stream

Event/Time News Detail
Loading, please wait...

VCNX Latest Social Stream

Loading social stream, please wait...

View Full VCNX Social Stream

Latest VCNX News From Around the Web

Below are the latest news stories about VACCINEX INC that investors may wish to consider to help them evaluate VCNX as an investment opportunity.

13 Best Biotech Penny Stocks To Buy Now

In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […]

Yahoo | November 29, 2022

Vaccinex Announces $3.8 Million Private Placement

ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that on November 23, 2022, the company closed the private placement of an aggregate of 7,142,496 shares of its common stock at a purchase price of $0.5293 per share for aggregate gross proceeds of approximately $3.8 million. The private placement wa

Yahoo | November 28, 2022

Vaccinex Third Quarter 2022 Earnings: US$0.11 loss per share (vs US$0.17 loss in 3Q 2021)

Vaccinex ( NASDAQ:VCNX ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.76m (loss narrowed by 8.6...

Yahoo | November 16, 2022

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the Phase 1b/2 KEYNOTE B84 oncology and Phase 1/2a SIGNAL-AD Alzheimer’s studies Several posters and presentations expected at November Medical Meetings, the Society for Immunotherapy of Cancer (SITC 2022) and Huntington’s Study Group

Yahoo | November 14, 2022

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D), and its collaborators at Emory University and the Moffitt Cancer Center today announced that two abstracts, including an oral presen

Yahoo | November 10, 2022

Read More 'VCNX' Stories Here

VCNX Price Returns

1-mo -6.66%
3-mo 3.06%
6-mo -42.72%
1-year -64.88%
3-year -91.81%
5-year N/A
YTD -8.46%
2022 -38.03%
2021 -49.76%
2020 -57.32%
2019 33.06%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8091 seconds.